Floatz logo

Becatecarin

Small Cell Lung Carcinoma

National Cancer Institute (NCI)Phase 2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

291 Active assets in the Small Cell Lung Carcinoma cohort.

Asset / SponsorPhaseRating
Benmelstobart
Yayi He
Phase 4A
vx-970
National Cancer Institute (NCI)
Phase 2BBB
Adebelimab
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3BBB
Veliparib
Central European Society for Anticancer Drug Research
Phase 2BB
hs-20093
Shanghai Hansoh Biomedical Co., Ltd
Phase 3BB

View all 50 →

Same molecule, other indications

Becatecarin is also rated in:

breast cancerDormant
CCC
Indicative ·
51 / 100
View asset →
breast carcinomaDormant
CCC
Indicative ·
51 / 100
View asset →
male breast carcinomaDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →